Seguir
Marcom
Marcom
Professor of Medicine, Duke University
Dirección de correo verificada de duke.edu
Título
Citado por
Citado por
Año
Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer
KD Miller, LI Chap, FA Holmes, MA Cobleigh, PK Marcom, ...
Journal of clinical oncology 23 (4), 792-799, 2005
17222005
Whole-genome analysis informs breast cancer response to aromatase inhibition
MJ Ellis, L Ding, D Shen, J Luo, VJ Suman, JW Wallis, BA Van Tine, ...
Nature 486 (7403), 353-360, 2012
12072012
Young age at diagnosis correlates with worse prognosis and defines a subset of breast cancers with shared patterns of gene expression
CK Anders, DS Hsu, G Broadwater, CR Acharya, JA Foekens, Y Zhang, ...
Journal of clinical oncology 26 (20), 3324-3330, 2008
10882008
Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer
SM Tolaney, WT Barry, CT Dang, DA Yardley, B Moy, PK Marcom, ...
New England Journal of Medicine 372 (2), 134-141, 2015
8772015
Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in …
HA Burris III, HI Hurwitz, EC Dees, A Dowlati, KL Blackwell, B O'Neil, ...
Journal of clinical oncology 23 (23), 5305-5313, 2005
8112005
Breast cancer, version 3.2020, NCCN clinical practice guidelines in oncology
WJ Gradishar, BO Anderson, J Abraham, R Aft, D Agnese, KH Allison, ...
Journal of the National Comprehensive Cancer Network 18 (4), 452-478, 2020
7822020
Circulating tumor cells from patients with advanced prostate and breast cancer display both epithelial and mesenchymal markers
AJ Armstrong, MS Marengo, S Oltean, G Kemeny, RL Bitting, JD Turnbull, ...
Molecular cancer research 9 (8), 997-1007, 2011
7672011
Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to …
AD Seidman, D Berry, C Cirrincione, L Harris, H Muss, PK Marcom, ...
Journal of Clinical Oncology 26 (10), 1642-1649, 2008
7222008
Randomized phase II neoadjuvant comparison between letrozole, anastrozole, and exemestane for postmenopausal women with estrogen receptor–rich stage 2 to 3 breast cancer …
MJ Ellis, VJ Suman, J Hoog, L Lin, J Snider, A Prat, JS Parker, J Luo, ...
Journal of clinical oncology 29 (17), 2342-2349, 2011
6652011
Changes in weight, body composition, and factors influencing energy balance among premenopausal breast cancer patients receiving adjuvant chemotherapy
W Demark-Wahnefried, BL Peterson, EP Winer, L Marks, N Aziz, ...
Journal of clinical oncology 19 (9), 2381-2389, 2001
6542001
TBCRC 001: randomized phase II study of cetuximab in combination with carboplatin in stage IV triple-negative breast cancer
LA Carey, HS Rugo, PK Marcom, EL Mayer, FJ Esteva, CX Ma, MC Liu, ...
Journal of clinical oncology 30 (21), 2615-2623, 2012
6072012
Cancer Yield of Mammography, MR, and US in High-Risk Women: Prospective Multi-Institution Breast Cancer Screening Study1
CD Lehman, C Isaacs, MD Schnall, ED Pisano, SM Ascher, PT Weatherall, ...
Radiology 244 (2), 381-388, 2007
4912007
Study of the biologic effects of lapatinib, a reversible inhibitor of ErbB1 and ErbB2 tyrosine kinases, on tumor growth and survival pathways in patients with advanced malignancies
NL Spector, W Xia, H Burris III, H Hurwitz, EC Dees, A Dowlati, B O'Neil, ...
Journal of clinical oncology 23 (11), 2502-2512, 2005
4812005
NCCN guidelines insights: breast cancer, version 1.2017
WJ Gradishar, BO Anderson, R Balassanian, SL Blair, HJ Burstein, A Cyr, ...
Journal of the national comprehensive cancer network 15 (4), 433-451, 2017
4732017
Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: multicenter phase II trial with clinical outcomes, analysis of serum tumor …
HJ Burstein, LN Harris, PK Marcom, R Lambert-Falls, K Havlin, ...
Journal of clinical oncology 21 (15), 2889-2895, 2003
4512003
Genetic/familial high-risk assessment: breast and ovarian
MB Daly, JE Axilbund, S Buys, B Crawford, CD Farrell, S Friedman, ...
Journal of the National Comprehensive Cancer Network 8 (5), 562-594, 2010
436*2010
Breast cancer, version 4.2017, NCCN clinical practice guidelines in oncology
WJ Gradishar, BO Anderson, R Balassanian, SL Blair, HJ Burstein, A Cyr, ...
Journal of the National Comprehensive Cancer Network 16 (3), 310-320, 2018
4252018
Invasive breast cancer version 1.2016, NCCN clinical practice guidelines in oncology
WJ Gradishar, BO Anderson, R Balassanian, SL Blair, HJ Burstein, A Cyr, ...
Journal of the National Comprehensive Cancer Network 14 (3), 324-354, 2016
3712016
Breast cancer version 2.2015
WJ Gradishar, BO Anderson, R Balassanian, SL Blair, HJ Burstein, A Cyr, ...
Journal of the National Comprehensive Cancer Network 13 (4), 448-475, 2015
370*2015
Genetic/familial high-risk assessment: breast and ovarian, version 2.2015
MB Daly, R Pilarski, JE Axilbund, M Berry, SS Buys, B Crawford, M Farmer, ...
Journal of the National Comprehensive Cancer Network 14 (2), 153-162, 2016
3442016
El sistema no puede realizar la operación en estos momentos. Inténtalo de nuevo más tarde.
Artículos 1–20